Dr Reddy’s refutes workforce cost cut claims as ‘factually incorrect’
Dr Reddy’s Laboratories has officially denied a report by Business Standard suggesting a 25% reduction in workforce costs, calling the article “factually incorrect.” In a statement released on April 14, the company emphasized that it does not comment on market speculations, while firmly rejecting claims related to senior-level exits or cost restructuring.
- The report had alleged that several senior executives, particularly those earning over ₹1 crore annually, were being asked to resign—a statement the company has categorically denied.
- Dr Reddy’s clarified that the claims made in the report do not reflect the company’s current strategy or internal decisions.
Operational efficiency does not imply cost cutting
The company, while denying layoffs, acknowledged its focus on enhancing operational efficiency, a common objective across the pharmaceutical industry. The speculation likely stemmed from analyst commentary, as cited in the original report, pointing to internal adjustments amid Revlimid-linked margin pressure.
- Dr Reddy’s has been actively expanding its portfolio, having entered the nutraceuticals market through a joint venture with Nestlé, and investing in digital therapeutics.
- To support these initiatives, the company has increased hiring, contrary to the speculation about workforce reduction.
Rising employee expenses signal continued hiring
Dr Reddy’s latest financials further contradict the layoff narrative. The company reported employee benefit expenses of ₹1,367 crore in Q3 FY25, reflecting a 7% increase over the ₹1,276 crore recorded in Q3 FY24.
- The rise in expenses signals not just retention but growth in workforce, especially as the company scales new verticals and launches new products.
- This data supports the company’s stance that it is not engaged in cost-cutting via layoffs, but is in fact investing in talent to fuel long-term strategies.
Share price under pressure despite company denial
Despite strong growth indicators and denial of the report, Dr Reddy’s stock has seen a nearly 19% decline in 2025. However, shares closed 1.46% higher at ₹1,110 on April 11, possibly reflecting investor confidence following the company’s response.
- The stock movement reflects market sensitivity to news surrounding cost structure and leadership changes, especially in volatile sectors like pharmaceuticals.
- The rebound may suggest that the clarification helped contain speculation, although broader investor sentiment remains cautious.
Dr Reddy’s Laboratories maintains that it is committed to innovation and strategic expansion, and the recent news report about downsizing is not aligned with actual company practices. As the company continues to diversify its product line and invest in new-age healthcare solutions, clarity around its human capital strategy remains essential for stakeholders.
